A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Running, not enrolling · Phase 2/Phase 3

Conditions studied: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

In brief

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Key facts

Study ID
NCT05002127
Run by
ALX Oncology Inc.
People needed
127
Starts
2022-01-15
Expected to finish
2026-06-01
Last updated by the study team
2025-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.